We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

134 hedge funds and large institutions have $1.39B invested in Blueprint Medicines in 2017 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 50 increasing their positions, 27 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 9

90% more capital invested

Capital invested by funds: $730M → $1.39B (+$657M)

85% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 27

47% more call options, than puts

Call options by funds: $2.84M | Put options by funds: $1.94M

30% more funds holding

Funds holding: 103 → 134 (+31)

29% more funds holding in top 10

Funds holding in top 10: 7 → 9 (+2)

23.39% more ownership

Funds ownership: 80.56% → 103.96% (+23%)

Holders
134
Holders Change
+31
Holders Change %
+30.1%
% of All Funds
3.34%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.22%
New
45
Increased
50
Reduced
27
Closed
9
Calls
$2.84M
Puts
$1.94M
Net Calls
+$903K
Net Calls Change
+$1.42M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$91.3M
2
BlackRock
BlackRock
New York
+$73.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$45.7M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$33.9M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$32.4M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$41.3M
2
DM
Deerfield Management
New York
-$17.1M
3
CAM
Cormorant Asset Management
Massachusetts
-$8.66M
4
SH
Sandia Holdings
Connecticut
-$7.47M
5
DCM
Driehaus Capital Management
Illinois
-$6.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Eventide Asset Management
Massachusetts
$10.6M – – –
FCMI
27
Foresite Capital Management III
California
$10.4M -$1.42M -39,600 -13%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$10.2M +$936K +26,128 +11%
Franklin Resources
29
Franklin Resources
California
$8M – – –
MIM
30
Monashee Investment Management
Massachusetts
$7M -$2.86M -80,000 Closed
CCM
31
Cadian Capital Management
New York
$6.99M +$6.26M +174,900 New
Fidelity International
32
Fidelity International
Bermuda
$6.9M -$3.03M -84,500 -33%
Citadel Advisors
33
Citadel Advisors
Florida
$6.86M +$3.47M +96,863 +130%
ACA
34
Avoro Capital Advisors
New York
$6.6M +$5.91M +165,000 New
Jennison Associates
35
Jennison Associates
New York
$6M +$5.37M +150,000 New
Two Sigma Investments
36
Two Sigma Investments
New York
$5.92M +$5.3M +148,105 New
JP Morgan Chase
37
JP Morgan Chase
New York
$5.79M -$794K -22,168 -13%
PC
38
PointState Capital
New York
$5.18M +$4.64M +129,500 New
GPP
39
Great Point Partners
Connecticut
$4.88M +$4.37M +122,129 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$4.82M +$970K +27,095 +29%
Charles Schwab
41
Charles Schwab
California
$4.5M +$1.01M +28,306 +34%
Point72 Asset Management
42
Point72 Asset Management
Connecticut
$4.12M +$3.69M +103,000 New
GTC
43
Ghost Tree Capital
New York
$4M +$3.58M +100,000 New
SIM
44
Spark Investment Management
New York
$3.59M -$75.2K -2,100 -2%
Morgan Stanley
45
Morgan Stanley
New York
$3.59M -$173K -4,825 -5%
DCM
46
DAFNA Capital Management
California
$3.3M +$358K +10,000 +14%
TCIM
47
TIAA CREF Investment Management
New York
$2.54M +$208K +5,795 +10%
Alyeska Investment Group
48
Alyeska Investment Group
Illinois
$2.39M -$1.44M -40,254 -40%
NC
49
NBW Capital
Massachusetts
$2.37M -$8.09K -226 -0.4%
LCM
50
Laurion Capital Management
New York
$2M -$362K -10,100 -17%
1
2
3 4 5

BPMC Hedge Fund Activity: Q1 2017 in Review

134 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2017, worth a combined $1.39B — up 90% from $730M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new BPMC positions and 9 closed out — a net gain of 36 holders — while 50 added to existing stakes and 27 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $91.3M. The largest seller was BVF Inc, cutting an estimated $41.3M.

  • 134 institutional investors held Blueprint Medicines (BPMC) as of Q1 2017, up from 103 in Q4 2016.
  • Funds reported $1.39B of Blueprint Medicines stock for Q1 2017, up 90% quarter-over-quarter.
  • 45 funds opened new Blueprint Medicines positions in Q1 2017 and 9 closed out, a net change of +36 holders.
  • The largest Blueprint Medicines buyer in Q1 2017 was Wellington Management Group, an estimated $91.3M added.
  • The largest Blueprint Medicines seller in Q1 2017 was BVF Inc, an estimated $41.3M sold.

Based on aggregated 13F filings for Q1 2017.